Vistagen receives new european patent for av-101

South san francisco, calif.--(business wire)---- $vtgn #cns--vistagen (nasdaq: vtgn) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced that the european patent office (epo) has granted the company a patent for av-101, its oral nmdar (n-methyl-d-aspartate receptor) glycine site antagonist.
VTGN Ratings Summary
VTGN Quant Ranking